| 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 葵花集团有限公司 | 26520.00 | 45.41 | 不变 | | 关彦斌 | 3522.04 | 6.03 | 不变 | | 黑龙江金葵投资股份有限公司 | 2400.00 | 4.11 | 不变 | | 中国平安人寿保险股份有限公司-分红-个险分红 | 411.03 | 0.70 | 新进 | | 中国平安人寿保险股份有限公司-自有资金 | 370.82 | 0.63 | 29.59 | | 中国银行股份有限公司-易方达中证红利交易型开放式指 数证券投资基金 | 359.80 | 0.62 | 22.71 | | 全国社保基金一零一组合 | 354.80 | 0.61 | -40.00 | | 张权 | 341.99 | 0.59 | 1.00 | | 李杰 | 328.16 | 0.56 | 不变 | | 上海浦东发展银行股份有限公司-招商中证红利交易型开 放式指数证券投资基金 | 291.30 | 0.50 | 新进 | | 较上个报告 ...

葵花药业2024年实现营收33.77亿元 净利润4.92亿元 智通财经4月25日电，葵花药业发布2024年报。年报显示，2024年度公司实现营业收入33.77亿元；归属 于上市公司股东的净利润4.92亿元；公司拟向全体股东每10股派发现金红利5元(含税)。 2024年，葵花药业通过实施"一老、一小、一妇"三大品类差异化竞争，以"实业+资本"双轮驱动，坚守 企业护城河。报告期内，公司不断优化儿童用药增长曲线规划，巩固第一曲线呼吸系统用药的行业地 位，培育第二曲线消化系统黄金产品，布局孵化第三曲线补益矿维类产品；成人用药持续巩固消化品类 布局，同时以独家品种石龙清血颗粒、补虚通瘀颗粒、脉络通、天菊脑安胶囊等特色产品拓展慢病的心 脑血管领域，以双虎肿痛宁喷雾剂、舒筋丸、活络消痛片等特色产品拓展风湿骨病领域共同发力，推动 慢病用药品类持续增长。 ...

葵花药业集团股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 葵花药业公司管理层根据中国证券监督管理委员会《上市公司监 管指引第 8 号——上市公司资金往来、对外担保的监管要求》（证监 会公告〔2022〕26 号）和《深圳证券交易所上市公司自律监管指南 第 1 号——业务办理》的相关规定编制了后附的 2024 年度非经营性 资金占用及其他关联资金往来情况汇总表（以下简称"汇总表"）。 编制汇总表并确保其真实、准确、完整是葵花药业公司管理层的 责任。我们将汇总表所载信息与我们审计葵花药业公司 2024 年度财 务报表时所审核的会计资料及已审计财务报表中披露的相关内容进 行了核对，没有发现在重大方面存在不一致的情况。 信会师报字[2025]第 ZB10801 号 葵花药业集团股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 | | 录 | 目 | 页 | 码 | | --- | --- | --- | --- | --- | | 一、 报告正文 | | | | 1-2 | | 2024 | 年度非经营性资金占用及其他关联资金往 | | | | | 二、 | 来情况汇总表 | | | ...

葵花药业集团股份有限公司 审计报告及财务报表 二○二四年度 葵花药业集团股份有限公司 审计报告及财务报表 （2024 年 01 月 01 日至 2024 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-131 | 审计报告 信会师报字[2025]第 ZB10799 号 葵花药业集团股份有限公司全体股东： 一、 审计意见 我们审计了葵花药业集团股份有限公司（以下简称葵花药业）财 务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公 司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的 规定编制，公 ...

葵花药业集团股份有限公司 内部控制审计报告 信会师报字[2025]第 ZB10800 号 葵花药业集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了葵花药业集团股份有限公司（以下简称葵花药业） 2024 年 12 月 31 日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 信会师报字[2025]第 ZB10800 号 葵花药业集团股份有限公司 内部控制审计报告 | | | 内部控制审计报告 四、 财务报告内部控制审计意见 我们认为，葵花药业于 2024 年 12 月 31 日按照《企业内部控制 基本规范》和相关规定在所有重大方面保持了有效的财务报告内部控 制。 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是葵花药业董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的 ...

Financial Performance - The company's revenue for Q1 2025 was ¥663,495,324.67, a decrease of 56.30% compared to ¥1,518,181,069.65 in the same period last year[5] - Net profit attributable to shareholders was ¥57,111,821.08, down 77.62% from ¥255,183,288.86 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥39,863,790.78, representing an 83.21% decline from ¥237,454,340.04 in the previous year[5] - Basic and diluted earnings per share were both ¥0.10, down 77.27% from ¥0.44 in the same period last year[5] - Net profit for the current period is ¥58,841,384.82, a decline of 78.2% from ¥270,303,238.96 in the previous period[19] Cash Flow - The net cash flow from operating activities was ¥101,710,569.51, a decrease of 50.21% compared to ¥204,290,572.95 in the same period last year[5] - Operating cash flow for the current period is ¥101,710,569.51, a decrease of 50.2% compared to ¥204,290,572.95 in the previous period[21] - Total cash inflow from operating activities is ¥740,744,371.24, down 52.5% from ¥1,556,556,156.54 in the previous period[21] - Cash outflow from operating activities is ¥639,033,801.73, a decrease of 52.8% compared to ¥1,352,265,583.59 in the previous period[21] - Cash flow from investment activities shows a net outflow of ¥200,286,889.86, contrasting with a net inflow of ¥1,006,831,858.31 in the previous period[22] - Cash and cash equivalents at the end of the period stand at ¥937,730,123.72, down 73.1% from ¥3,495,677,467.15 in the previous period[22] - The net increase in cash and cash equivalents for the current period is -¥100,230,574.79, a significant decline from an increase of ¥1,209,972,261.26 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,774,405,931.02, a decrease of 0.88% from ¥5,825,875,967.73 at the end of the previous year[5] - Total liabilities are ¥1,125,647,233.48, down from ¥1,235,876,758.46 in the previous period[16] - Total current assets are reported at ¥3,882,717,982.71, slightly down from ¥3,885,593,091.44 at the beginning of the period[14] - Accounts receivable stand at ¥206,995,831.79, showing a slight decrease from ¥207,740,418.62[14] - Inventory decreased to ¥786,664,048.65 from ¥867,310,798.53, a decline of approximately 9.3%[14] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 55,081[11] - The largest shareholder, KuaHua Group Co., Ltd., holds 45.41% of shares, totaling 265,200,000 shares[11] - Shareholders' equity attributable to the parent company increased by 1.30% to ¥4,436,250,289.82 from ¥4,379,138,713.78 at the end of the previous year[5] - Total equity attributable to shareholders of the parent company is ¥4,436,250,289.82, an increase from ¥4,379,138,713.78 in the previous period[16] Expenses and Costs - Total operating costs for the current period are ¥612,330,871.14, down 48.9% from ¥1,198,310,855.92 in the previous period[18] - Research and development expenses for the current period are ¥20,190,757.43, a decrease of 12.3% from ¥22,993,910.90 in the previous period[18] - The company reported a financial asset impairment loss of ¥1,143,003.30 for the current period, compared to ¥1,859,231.83 in the previous period[19] - The company reported a significant reduction in sales expenses by 79.19% to ¥82,215,847.30 from ¥395,103,030.63 in the previous year, due to enhanced cost control[9] Investment Activities - Investment income decreased by 46.27% to ¥2,905,256.09 from ¥5,407,601.03 in the same period last year, primarily due to reduced returns from maturing financial products[9] - The company received ¥1,554,983,011.00 from investment recoveries, which is a substantial increase from ¥1,000,000,000.00 in the previous period[22] Future Plans - The company has announced plans for new product registrations, including Ibuprofen suspension and PEG 3350 powder, expected to enhance market offerings[12] - The company is in the process of increasing capital for its subsidiaries, indicating a strategy for expansion[12] Audit Status - The company has not yet audited the first quarter report for 2025[23]

葵花药业集团股份有限公司 关于磷酸奥司他韦干混悬剂获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：002737 证券简称：葵花药业 公告编号：2025-012 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）子公司于近 日收到国家药品监督管理局下发的关于磷酸奥司他韦干混悬剂获批注册的药品 注册证书，现将有关情况公告如下： 一、 药物的基本情况 1、药品通用名称：磷酸奥司他韦干混悬剂 2、主要成份：磷酸奥司他韦 3、申请事项：药品注册(境内生产) 4、规格：0.36g(按 C16H28N2O4 计) 5、注册分类：化学药品 3 类 6、处方药/非处方药：处方药 7、药品批准文号：国药准字 H20253868 8、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明 书、标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范 要求方可生产销售。 9、适应症： (1) 用于成人和 2 周龄及以上儿童的甲型和乙型流感治疗（磷酸奥司他韦 ...

仿制药入局易对标难 儿童退热市场等待"中国答案" 据《 2016 中国儿童用药安全白皮书》，我国约有五成儿童用药不规范，每年因用药不当 导致失聪的儿童病例超 3 万例，致死案例超 7000 例。 数据显示，我国 2400 种儿童化学药中，专用化药不足 5% ，儿童依从性更好的口服溶液 剂、混悬剂不足 10% 。在退热药市场，"美林"长期占据国内线下药店终端超 90% 份额， 其缺货期间 3000 元每瓶的黄牛价更暴露市场畸形现状。 同时需要指出的是，仿制药入局易，对标却难。据 CDE 数据，国内目前已有 28 个布洛芬 混悬液生产批件，但由于家长普遍认为原研药质量更好、疗效更为稳定，因而给儿童选择药 物时更倾向于选择品牌知名度高的原研药，导致仿制药难以进入市场，实际生产规模十分有 限，强生制药的原研药物"美林"依旧一家独大。 近年来，患者对于仿制药质量问题的疑虑似乎从未真正消失过。从医生反应"麻药不 麻"、"泻药不泻"，到仿制药一致性评价数据雷同，再到 FDA 对多家中国药品检测公司发 出检测数据警告，仿制药的信任危机不断发酵，甚至愈发强烈。 高品质国药崛起正当时 近日，葵花药业宣布旗下重庆小葵花儿童制药有限 ...

Core Viewpoint - The approval of ibuprofen suspension by Kew Flower Pharmaceutical marks a significant step towards addressing the limited options in the domestic children's medication market, indicating the entry of high-quality domestic children's antipyretics into a new era of "quality equality" [1] Group 1: Market Context - Approximately 50% of children's medications in China are used improperly, leading to over 30,000 cases of hearing loss and more than 7,000 deaths annually due to improper medication [3] - Only 5% of the 2,400 types of chemical drugs for children are specifically formulated, and less than 10% are oral solutions or suspensions that are easier for children to take [3] - The antipyretic market is dominated by "Meilin," which holds over 90% market share in offline pharmacies, highlighting the distorted market situation [3][5] Group 2: Challenges for Generic Drugs - While there are currently 28 production licenses for ibuprofen suspension in China, parents tend to prefer original branded drugs due to perceived quality and efficacy, making it difficult for generic drugs to penetrate the market [3][5] - The trust crisis surrounding generic drugs has been exacerbated by concerns over quality, with reports of inconsistencies in efficacy and safety [3][5] Group 3: Quality and Innovation - Kew Flower Pharmaceutical's ibuprofen suspension has been developed to meet international quality standards, with key efficacy parameters matching those of Johnson & Johnson's "Meilin" [5][6] - The company has established 18 internal raw material control standards, exceeding pharmacopoeia standards by 8, and has improved content accuracy and drug release rates by 10% [7] - The product features a child-friendly strawberry flavor and a specially designed child-proof cap to enhance user experience and reduce the risk of accidental ingestion [7] Group 4: Strategic Expansion - Kew Flower Pharmaceutical is deepening its focus on children's health, having established a formulation research institute and partnered with universities to expand its product matrix [10] - The newly approved ibuprofen suspension and drops are part of a comprehensive product matrix that addresses various pediatric health needs, including fever and cough [10][11] - The company has built a portfolio of over 70 children's medications across seven therapeutic areas, achieving over 30% market share in the OTC children's medication market [11] Group 5: Sales Performance - Kew Flower Pharmaceutical has nearly 30 products with sales exceeding 100 million, with the "Little Kew Flower" brand selling over 300 million boxes annually [11] - The "Little Kew Flower" pediatric cough syrup achieved sales of over 400 million in 2023, reflecting a growth rate of 22.4% [11] - The company's success is attributed to its commitment to quality and user needs, positioning it well for future growth in the pediatric medication sector [11]

证券代码：002737 证券简称：葵花药业 公告编号：2025-011 葵花药业集团股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 经葵花药业集团股份有限公司（以下简称"公司"）第四届董事会第二十九 次会议、第四届监事会第二十二次会议、公司 2023 年年度股东大会审议通过， 公司决定使用额度不超过 200,000 万元的闲置自有资金进行现金管理，存续期为 自股东大会审议通过之日起 12 个月内，在已审议的额度、期限内，资金可循环 滚动使用。 授权董事长在上述期限和额度内，行使本次现金管理的决策权并签署相关法 律文件，由公司财务部门负责具体实施。 有关上述具体内容详见《中国证券报》、《证券时报》、巨潮资讯网 （http:www.cninfo.com.cn）公司公告。 一、本次进行现金管理的实施进展情况 根据上述决议，公司于近日使用闲置自有资金 40,000 万元购买了部分理财 产品，具体情况如下： | 序 | | | | 金额 | | | 预期年化收 | 资金 | | --- | --- | --- | ...